Revenues
MAC
Macerich (NYSE:MAC) received mixed analyst ratings over the past three months, with a recent shift towards a more bearish outlook. The average 12-month price target for MAC is now $15.2, reflecting a 1.94% decrease from the previous target. Analysts from Compass Point, Mizuho, Piper Sandler, Truist Securities, and Citigroup have adjusted their ratings and price targets, indicating varying expectations for the company's performance. Macerich, an S&P 500 company, owns a significant portfolio of mall assets but shows a lower market capitalization and financial performance below industry averages.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 7:01 pm
ENTG
Entegris (NASDAQ:ENTG) has received mixed analyst ratings over the past three months, with 11 analysts offering evaluations. The ratings range from bullish to indifferent, with no bearish sentiments. The average 12-month price target for ENTG is $146.82, marking a significant increase from the previous target of $121.38. Analysts from firms like Needham, Mizuho, Citigroup, BMO Capital, Keybanc, Craig-Hallum, Goldman Sachs, and UBS have adjusted their ratings and price targets, reflecting various perspectives on the company's performance and market position. Entegris, a supplier of materials and process solutions for high-technology industries, has seen a revenue decline of -14.14% over the last three months but maintains a strong net margin of 4.68%. However, its market capitalization, ROE, ROA, and high debt-to-equity ratio indicate potential financial challenges.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 7:01 pm
DFIN
Analysts have mixed views on Donnelley Financial Solns (DFIN), with recent ratings showing a bullish trend. The average 12-month price target is set at $72.00, marking a 13.08% increase from the previous target. The company's financial performance shows positive revenue growth but challenges in net margin and ROA, while excelling in ROE and managing debt well.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 7:00 pm
ZBRA
Analyst opinions on Zebra Technologies (NASDAQ:ZBRA) have shown a positive shift over the past quarter, with recent ratings becoming more bullish. The average 12-month price target for ZBRA has increased to $338.78, up 6.59% from the previous $317.83. Analysts from firms like UBS, Stephens & Co., and Truist Securities have raised their price targets, reflecting optimism about the company's performance despite a significant revenue decline of -32.87% as of December 31, 2023. Zebra Technologies, known for its automatic identification and data capture technology, faces challenges in revenue growth but excels in net margin, ROE, and ROA, indicating efficient cost management and financial health.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 7:00 pm
CECO
CECO Environmental (NASDAQ:CECO) has received diverse analyst ratings over the past quarter, with a total of 7 analysts offering opinions ranging from bullish to bearish. The recent ratings show an increase in bullish sentiment, with 3 new bullish ratings in the last 30 days. The average 12-month price target for CECO has risen to $27.14, up 15.49% from the previous target of $23.50. Analysts from firms like Craig-Hallum, Needham, HC Wainwright & Co., Northland Capital Markets, and Roth MKM have adjusted their ratings and price targets, reflecting optimism about CECO's market position and financial performance. CECO Environmental, serving various markets including energy, industrial, and others, has shown remarkable revenue growth of 32.05% and strong financial metrics such as net margin, ROE, and ROA, outperforming industry standards.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 7:00 pm
ACB
CGC
CURLF
GTBIF
TCNNF
TLRY
Following the DEA's announcement to reschedule cannabis, the market cap of major cannabis firms has seen significant changes. Curaleaf, Canopy, Tilray, Aurora, Green Thumb Industries, and Trulieve have experienced fluctuations in market capitalization since their public debuts. The total economic impact of regulated marijuana sales in the U.S. is expected to surpass $112.4 billion in 2024, with sales forecasted to reach $32.1 billion. Market cap growth varies among companies, with some experiencing decreases and others increases.
Portfolio Pulse from
Nicolás Jose Rodriguez
May 01, 2024 | 6:25 pm
MMSI
Merit Medical Systems (NASDAQ:MMSI) has been the subject of diverse analyst ratings over the last three months, with 11 analysts offering views that range from bullish to bearish. The recent ratings show a mix of 5 bullish, 5 somewhat bullish, and 1 indifferent, with an upward trend in the 12-month price target to an average of $93.45. Analyst actions include both raises and lowers in ratings and price targets, reflecting ongoing market conditions and company performance. Merit Medical Systems, a medical equipment company, has shown solid financial performance with a revenue growth rate of 10.6%, a net margin of 8.51%, and strong ROE and ROA figures.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 6:01 pm
PCAR
PACCAR (NASDAQ:PCAR) has been analyzed by 8 analysts in the last three months, showing a mix of bullish to bearish sentiments. Recent ratings indicate a shift towards a more positive outlook, with an average 12-month price target of $125.38, marking an 8.24% increase from the previous target. Analyst actions include both upgrades and downgrades, reflecting responses to market conditions and PACCAR's performance. The company, known for its medium- and heavy-duty trucks, has shown strong financial health with a revenue growth of 11.65%, a net margin of 15.61%, and above-average ROE and ROA.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 6:01 pm
GTHX
Five financial analysts have recently updated their ratings on G1 Therapeutics (NASDAQ:GTHX), showing a predominantly bullish outlook with four bullish and one somewhat bullish ratings. The 12-month price targets suggest an average of $10.4, with a high of $12.00 and a low of $4.00, indicating a 9.47% increase from the previous average target of $9.50. Analyst actions include maintaining and lowering ratings, reflecting responses to market dynamics and company performance. G1 Therapeutics, a biopharmaceutical company focused on cancer treatment, has shown a revenue growth of 45.1% but faces challenges in debt management and efficiency in using equity capital.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 6:01 pm
FN
Five analysts have recently published their ratings on Fabrinet (NYSE:FN), showing a mix of bullish, somewhat bullish, and indifferent perspectives. Over the last three months, there have been no changes in these ratings. The 12-month price targets for FN have an average of $216.4, with a high of $230 and a low of $200, marking a slight increase from the previous average target. Analysts from firms like JP Morgan, Needham, and Northland Capital Markets have adjusted their ratings and price targets, reflecting their views on Fabrinet's market dynamics and performance. Fabrinet, a provider of outsourced manufacturing services, has shown strong financial performance with significant revenue growth, high net margin, and excellent ROE and ROA, positioning it well above industry averages.
Portfolio Pulse from
Benzinga Insights
May 01, 2024 | 6:00 pm
Previous
Next
